Ainos, Inc. (NASDAQ:AIMD) Sees Significant Decrease in Short Interest

Ainos, Inc. (NASDAQ:AIMD) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 113,000 shares, a decline of 21.1% from the October 31st total of 143,300 shares. Currently, 4.5% of the company’s stock are sold short. Based on an average daily trading volume, of 351,500 shares, the days-to-cover ratio is presently 0.3 days.

Ainos Stock Down 1.7 %

NASDAQ:AIMD opened at $0.47 on Monday. The business’s fifty day moving average price is $0.49 and its 200 day moving average price is $0.66. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.33. Ainos has a 1-year low of $0.40 and a 1-year high of $4.29.

Ainos (NASDAQ:AIMD) last released its earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share for the quarter. Ainos had a negative net margin of 15,348.14% and a negative return on equity of 75.16%.

About Ainos

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.